Open AccessS837 Payor-Mandated Non-Medical Switching From Infliximab to Biosimilar Creates Dosing Delays
Author(s) -
Samantha A. Mehta,
Timothy E. Ritter,
Christopher C. Fernandes,
Siri Tummala,
Brooklin C. Smith,
Lucinda J. Van Anglen
Publication year - 2021
Publication title -
the american journal of gastroenterology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.907
H-Index - 252
eISSN - 1572-0241
pISSN - 0002-9270
DOI - 10.14309/01.ajg.0000776880.16345.04
Subject(s) - infliximab , medicine , biosimilar , dosing , ulcerative colitis , inflammatory bowel disease , regimen , surgery , disease